Quince Therapeutics, Inc.

NasdaqGS:QNCX Stock Report

Market Cap: US$78.3m

Quince Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:QNCX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Aug 24BuyUS$107,375Dirk ThyeIndividual154,500US$0.70
21 Aug 24BuyUS$24,166Brendan HannahIndividual38,924US$0.63
20 Aug 24BuyUS$31,452Charles RyanIndividual48,387US$0.65

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of QNCX?
Owner TypeNumber of SharesOwnership Percentage
Public Companies189,1220.43%
VC/PE Firms2,525,9505.74%
Individual Insiders5,947,87213.5%
Institutions7,179,60316.3%
General Public28,159,09664%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.6%.

Top Shareholders

Top 25 shareholders own 35.66% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.96%
David Lamond
4,384,096US$7.8m0%no data
5.74%
Genextra S.p.A.
2,525,950US$4.5m0%100.0%
4.9%
Sofinnova Partners SAS
2,155,694US$3.8m-1.03%2.67%
2.73%
The Vanguard Group, Inc.
1,199,648US$2.1m-1.23%no data
1.92%
Dirk Thye
843,941US$1.5m22.4%no data
1.88%
EPIQ Capital Group, LLC
825,942US$1.5m-3.1%0.39%
1.19%
Renaissance Technologies LLC
522,576US$930.2k7.99%no data
0.87%
Almitas Capital LLC
382,882US$681.5k0%0.15%
0.81%
BlackRock, Inc.
358,358US$637.9k1.01%no data
0.78%
HighTower Advisors, LLC
341,570US$608.0k0%no data
0.77%
Geode Capital Management, LLC
339,125US$603.6k24.2%no data
0.67%
Brendan Hannah
296,540US$527.8k15.1%no data
0.44%
Karen Smith
194,690US$346.5k0%no data
0.43%
Alphabet Inc.
189,122US$336.6k0%no data
0.39%
Shay Capital LLC
172,183US$306.5k0%0.08%
0.35%
Merrill Lynch & Co. Inc., Banking Investments
152,736US$271.9k0%no data
0.32%
ADAR1 Capital Management, LLC
142,958US$254.5k53.8%0.05%
0.28%
Mariner, LLC
122,461US$218.0k65.3%no data
0.28%
Charles Ryan
122,461US$218.0k65.3%no data
0.24%
Citadel Advisors LLC
107,007US$190.5k7.17%no data
0.2%
Bridgeway Capital Management, LLC
88,495US$157.5k-36.1%no data
0.18%
Luca Benatti
80,261US$142.9k0%no data
0.13%
State Street Global Advisors, Inc.
56,611US$100.8k0%no data
0.12%
Intellectus Partners, LLC
53,527US$95.3k0.4%0.02%
0.077%
Northern Trust Global Investments
34,023US$60.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 22:22
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Quince Therapeutics, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Kumaraguru RajaBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity